Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia

NCT00139061 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00139061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00139061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2005
Completion date
May 31, 2006
Enrollment
128
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia